115 related articles for article (PubMed ID: 15044577)
1. Screening for Hepatitis C in injecting drug users: a cost utility analysis.
Stein K; Dalziel K; Walker A; Jenkins B; Round A; Royle P
J Public Health (Oxf); 2004 Mar; 26(1):61-71. PubMed ID: 15044577
[TBL] [Abstract][Full Text] [Related]
2. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users?
Leal P; Stein K; Rosenberg W
J Med Screen; 1999; 6(3):124-31. PubMed ID: 10572842
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
Kim DD; Hutton DW; Raouf AA; Salama M; Hablas A; Seifeldin IA; Soliman AS
Glob Public Health; 2015; 10(3):296-317. PubMed ID: 25469976
[TBL] [Abstract][Full Text] [Related]
5. Screening for hepatitis C in genito-urinary medicine clinics: a cost utility analysis.
Stein K; Dalziel K; Walker A; Jenkins B; Round A; Royle P
J Hepatol; 2003 Nov; 39(5):814-25. PubMed ID: 14568266
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.
John-Baptiste A; Yeung MW; Leung V; van der Velde G; Krahn M
Pharmacoeconomics; 2012 Nov; 30(11):1015-34. PubMed ID: 23050771
[TBL] [Abstract][Full Text] [Related]
7. Case finding for hepatitis C in primary care: a cost utility analysis.
Thompson Coon J; Castelnuovo E; Pitt M; Cramp M; Siebert U; Stein K
Fam Pract; 2006 Aug; 23(4):393-406. PubMed ID: 16799165
[TBL] [Abstract][Full Text] [Related]
8. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?
Sheerin IG; Green FT; Sellman JD
Drug Alcohol Rev; 2004 Sep; 23(3):261-72. PubMed ID: 15370005
[TBL] [Abstract][Full Text] [Related]
9. Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis.
Girardin F; Hearmon N; Negro F; Eddowes L; Bruggmann P; Castro E
J Viral Hepat; 2019 Feb; 26(2):236-245. PubMed ID: 30338887
[TBL] [Abstract][Full Text] [Related]
10. HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations.
Tramarin A; Gennaro N; Compostella FA; Gallo C; Wendelaar Bonga LJ; Postma MJ
Curr Pharm Des; 2008; 14(17):1655-60. PubMed ID: 18673188
[TBL] [Abstract][Full Text] [Related]
11. Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison.
Sutton AJ; Edmunds WJ; Gill ON
BMC Public Health; 2006 Jun; 6():170. PubMed ID: 16803622
[TBL] [Abstract][Full Text] [Related]
12. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults.
Singer ME; Younossi ZM
Am J Med; 2001 Dec; 111(8):614-21. PubMed ID: 11755504
[TBL] [Abstract][Full Text] [Related]
14. Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users.
Martin NK; Pitcher AB; Vickerman P; Vassall A; Hickman M
PLoS One; 2011; 6(8):e22309. PubMed ID: 21853030
[TBL] [Abstract][Full Text] [Related]
15. The testing of people with any risk factor for hepatitis C in community pharmacies is cost-effective.
Buchanan R; Cooper K; Grellier L; Khakoo SI; Parkes J
J Viral Hepat; 2020 Jan; 27(1):36-44. PubMed ID: 31520434
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
17. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England.
Williams J; Miners A; Harris R; Mandal S; Simmons R; Ireland G; Hickman M; Gore C; Vickerman P
Value Health; 2019 Nov; 22(11):1248-1256. PubMed ID: 31708061
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations.
Coward S; Leggett L; Kaplan GG; Clement F
BMJ Open; 2016 Sep; 6(9):e011821. PubMed ID: 27601496
[TBL] [Abstract][Full Text] [Related]
20. Who to screen for hepatitis C? A cost-effectiveness study in Belgium of comprehensive hepatitis C screening in four target groups.
Opstaele L; Bielen R; Bourgeois S; Moreno C; Nevens F; Robaeys G; Robaeys G; Van Vlierberghe H
Acta Gastroenterol Belg; 2019; 82(3):379-387. PubMed ID: 31566325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]